Keila Barral – Founder & CEO, Cromodata
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Address: Via Scuderlando 10 – 37135 Verona,Italy
Tel: +39 045.8222811
Web: http://www.cromsource.com/
CROM is a Contract Research Organisation based in Verona that was launched in 1997. The company also has activities in Poland, Ukraine, Bulgaria, Russia and the Czech Republic.
It offers its customers a broad range of services, from clinical project management and clinical trial monitoring to training seminars.
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role…
Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how…
You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the development of new drugs. The decree…
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector…
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics. The deal, said to…
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases. We are very excited…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community, their core mission of translational medicine and the challenges Italy faces today with the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in academic research. Division director Professor Gianvito Martino discusses the institute’s unique operative…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute, discusses the crucial role the OBT occupies as a link between the industry…
Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of…
Thilo Stadler speaks passionately about Grünenthal’s collaborative partnerships, company goals, and workforce engagement; revealing himself to be someone who truly believes in Grünenthal’s business. You currently hold the position of…
Digitalization, a hot topic throughout the healthcare and life sciences industry, is having a major effect in Italy through more personalized home care for patients, allowing the government to cut costs,…
Regardless of external challenges, the Italian pharmaceutical industry is clearly equipped for success, in terms of physical capital, expertise, and culture. There is a “Made in Italy” element in pharmaceuticals…
See our Cookie Privacy Policy Here
